Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Seminars in Hematology|April 3, 2008
Antibody therapy for chronic lymphocytic leukemiaBeth A Christian, Thomas S LinClinical Lymphoma & Myeloma|September 26, 2009
Flavopiridol in chronic lymphocytic leukemia: a concise reviewBeth A Christian, Michael R Grever, John C Byrd, et al.Current Opinion in Oncology|October 2, 2007
Flavopiridol in the treatment of chronic lymphocytic leukemiaBeth A Christian, Michael R Grever, John C Byrd, et al.Leukemia & Lymphoma|November 15, 2016
Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting doseDavid A Bond, Ying Huang, Amy S Ruppert, et al.Blood Advances|November 17, 2021
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomasMegan Fleming, Ying Huang, Emily Dotson, et al.Clinical Lymphoma, Myeloma & Leukemia|February 10, 2015
Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphomaJonathon B Cohen, Amy S Ruppert, Nyla A Heerema, et al.Clinical Lymphoma, Myeloma & Leukemia|June 18, 2017
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin LymphomaJoseph J Maly, Beth A Christian, Xiaohua Zhu, et al.British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.Blood|January 14, 2011
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphomaLapo Alinari, Bo Yu, Beth A Christian, et al.Cancer|March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survivalJonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.Pageof 2